| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/04/2001 | US6284272 Pharmaceutical compositions containing an effervescent acid-base couple |
| 09/04/2001 | US6284271 Multiple unit effervescent dosage form |
| 09/04/2001 | US6284270 Means for creating a mass having structural integrity |
| 09/04/2001 | US6284269 Pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
| 09/04/2001 | US6284265 Antacid formulation |
| 09/04/2001 | US6284264 Water soluble film for oral administration with instant wettability |
| 09/04/2001 | US6284250 Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media |
| 09/04/2001 | US6284246 Modified polypeptides with high activity and reduced allergenicity |
| 09/04/2001 | US6284234 Topical delivery systems for active agents |
| 09/04/2001 | US6284226 Aerosol composition containing middle-chain fatty acid triglyceride dispersant |
| 09/04/2001 | US6284140 Dialysis solution for peritoneal dialysis |
| 09/04/2001 | CA2086120C Topical ophthalmic suspensions |
| 09/04/2001 | CA2050298C Dry powder inhalation device |
| 09/04/2001 | CA2039491C Stable compositions for parenteral administration and method of making same |
| 09/04/2001 | CA2037410C Therapeutic compositions with controlled release of medicaments supported on crosslinked polymers and coated with polymer films, and their preparation process |
| 09/04/2001 | CA2019779C Intermittent release dosage form |
| 08/30/2001 | WO2001063290A1 Bcmp-7 as marker for diagnosis of breast cancer |
| 08/30/2001 | WO2001063289A1 Diagnosis of breast cancer using bcmp-11 as marker |
| 08/30/2001 | WO2001063288A1 Diagnosis of breast cancer using bcmp-81 as marker |
| 08/30/2001 | WO2001062931A2 ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF |
| 08/30/2001 | WO2001062914A1 Bcmp 84, a protein associated to breast cancer |
| 08/30/2001 | WO2001062827A2 N-maleimidyl polymer derivatives |
| 08/30/2001 | WO2001062809A1 Cosmetic agent |
| 08/30/2001 | WO2001062784A2 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | WO2001062774A2 Purified lh |
| 08/30/2001 | WO2001062312A1 Foam-forming wound dressing |
| 08/30/2001 | WO2001062300A2 Caspase activated prodrugs therapy |
| 08/30/2001 | WO2001062299A2 Water-soluble polymer conjugates of artelinic acid |
| 08/30/2001 | WO2001062298A2 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 08/30/2001 | WO2001062297A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | WO2001062296A2 Non-aqueous injectable formulations for extended release of somatotropin |
| 08/30/2001 | WO2001062288A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | WO2001062286A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | WO2001062283A2 Mucosal adjuvant formulation |
| 08/30/2001 | WO2001062276A1 A stable composition comprising epidermal growth factor as an active ingredient |
| 08/30/2001 | WO2001062268A1 Endoparasiticidal agents |
| 08/30/2001 | WO2001062256A1 Novel galenical form for oral administration with prolonged release of molsidomine |
| 08/30/2001 | WO2001062254A1 Patches containing buprenorphine hydrochloride |
| 08/30/2001 | WO2001062248A1 Orally administrable acid stable anti-ulcer benzimidazole derivatives |
| 08/30/2001 | WO2001062232A1 Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use |
| 08/30/2001 | WO2001062231A1 Antibiotic composition with inhibitor |
| 08/30/2001 | WO2001062228A1 Method for transdermal or intradermal delivery of molecules |
| 08/30/2001 | WO2001062217A2 Oil-based cosmetics containing water-soluble actives |
| 08/30/2001 | WO2001062214A1 Gelled aqueous cosmetic compositions |
| 08/30/2001 | WO2001062207A2 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 08/30/2001 | WO2001062108A1 Water containing soluble fiber |
| 08/30/2001 | WO2001062086A1 Nutritional intervention composition for enhancing and extending satiety |
| 08/30/2001 | WO2001062085A1 Protected forms of pharmacologically active agents and uses therefor |
| 08/30/2001 | WO2001026705A3 A dual adhesive transdermal drug delivery system |
| 08/30/2001 | WO2001025248A3 Design of high affinity rnase h recruiting oligonucleotide |
| 08/30/2001 | WO2001024842A3 Hybrid matrices and hybrid matrix mixtures |
| 08/30/2001 | WO2001013927A3 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 08/30/2001 | WO2001010430A3 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 08/30/2001 | WO2001010378A3 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 08/30/2001 | US20010018509 Growth differeniation factor-3 |
| 08/30/2001 | US20010018508 Tumour necrosis factor binding ligands |
| 08/30/2001 | US20010018507 Complexing |
| 08/30/2001 | US20010018489 Graft polymer of vinyl ester and polyether |
| 08/30/2001 | US20010018432 Skin disorders; acne, seborrhea |
| 08/30/2001 | US20010018426 Lithium chloride |
| 08/30/2001 | US20010018421 Polypeptides |
| 08/30/2001 | US20010018420 Method for alleviating pain or providing an analgesic effect in a patient |
| 08/30/2001 | US20010018417 Of sodium lauryl sulfate, a buffering agent to provide acidic pH when the mixture is added to water, and colloidal silica; mixture added to animal feeds |
| 08/30/2001 | US20010018073 Drug delivery; steroids or hormones penetrate due to combination with destructuring agent and structuring agent in common matrix; useful in treatment of hypogonadism, infertility, or contraception |
| 08/30/2001 | US20010018072 Solid matrix therapeutic compositions |
| 08/30/2001 | US20010018071 Oral 2-methyl-thieno-benzodiazepine formulation |
| 08/30/2001 | US20010018070 Extending the duration of drug release within the stomach during the fed mode |
| 08/30/2001 | US20010018065 Administering drugs comprised of antibiotic, carrier, and oligosaccharide-support which binds and removes shiga-like toxins from gastrointestinal tract; Escherichia; enterotoxins; antidiarrhetics |
| 08/30/2001 | US20010018049 Methods and compositions for the treatment of pancreatitis |
| 08/30/2001 | DE10008948A1 L-Ascorbinsäure und NaCl als Carrier zur Hormon-No-und Enzymsynthese L-ascorbic acid and NaCl as a carrier for hormone-No-and enzyme synthesis |
| 08/30/2001 | DE10008508A1 New polycarbonate with cyclodextrin units, used e.g. as a chromatographic stationary phase, catalyst, drug delivery system, extractant or moulding material, especially for removing organic compounds from water |
| 08/30/2001 | DE10008263A1 Cosmetic composition, especially useful as hair spray, includes water-soluble or water-dispersible polymer containing t-butyl (alk)acrylate or N-t-butyl (alk)acrylamide units |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2400953A1 Orally administrable acid stable anti-ulcer benzimidazole derivatives |
| 08/30/2001 | CA2400874A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | CA2400661A1 Novel antibody with specificity for colon cancer |
| 08/30/2001 | CA2400610A1 Endoparasiticidal compositions comprising a cyclic depsipeptide |
| 08/30/2001 | CA2400099A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | CA2399999A1 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | CA2399550A1 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 08/30/2001 | CA2399255A1 Caspase activated prodrugs therapy |
| 08/30/2001 | CA2399211A1 Foam-forming wound dressing |
| 08/30/2001 | CA2394088A1 Method for transdermal or intradermal delivery of molecules |
| 08/30/2001 | CA2368665A1 Oil-based cosmetics containing water-soluble actives |
| 08/30/2001 | CA2368364A1 A stable composition comprising epidermal growth factor as an active ingredient |
| 08/29/2001 | EP1127580A2 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 08/29/2001 | EP1127579A2 Method for increasing bioavailability of oral pharmaceutical compositions |
| 08/29/2001 | EP1127578A1 Remedies for bone metabolic errors |
| 08/29/2001 | EP1127570A2 Production process for polymeric micelle composition charged therein with drug |
| 08/29/2001 | EP1127355A1 Products and methods for brachytherapy |
| 08/29/2001 | EP1127136A1 Delivery of superoxide dismutase to neuronal cells |
| 08/29/2001 | EP1127119A1 Compounds and methods for modulating claudin-mediated functions |
| 08/29/2001 | EP1127115A1 Antisense oligomer |
| 08/29/2001 | EP1127110A1 Modified exosomes and uses |
| 08/29/2001 | EP1126882A2 Stable preparations with hyperforin |
| 08/29/2001 | EP1126881A1 Muco-adhesive polymers, use thereof and method for producing the same |
| 08/29/2001 | EP1126875A2 Pharmaceutically active composition and dispensing device |
| 08/29/2001 | EP1126848A1 Plastics container containing stabilised drug formulations |
| 08/29/2001 | EP1126830A1 Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents |
| 08/29/2001 | EP1126829A1 Particles coated with granulated crystalline ibuprofen |